Kinase hinge binding scaffolds and their hydrogen bond patterns.
暂无分享,去创建一个
Li Xing | Elizabeth A Lunney | Jacquelyn L. Klug-McLeod | E. Lunney | L. Xing | B. Rai | Jacquelyn Klug-Mcleod | Brajesh Rai
[1] Paul A. Bartlett,et al. Differential binding energy: a detailed evaluation of the influence of hydrogen-bonding and hydrophobic groups on the inhibition of thermolysin by phosphorus-containing inhibitors , 1991 .
[2] L. Johnson,et al. Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.
[3] L. Otterbein,et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. , 2006, Journal of medicinal chemistry.
[4] P. Caron,et al. Classifying protein kinase structures guides use of ligand‐selectivity profiles to predict inactive conformations: Structure of lck/imatinib complex , 2007, Proteins.
[5] A. Caflisch,et al. Current kinase inhibitors cover a tiny fraction of fragment space. , 2015, Bioorganic & medicinal chemistry letters.
[6] Li Xing,et al. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804. , 2009, Biochemistry.
[7] C. Grütter,et al. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. , 2008, Bioorganic & medicinal chemistry.
[8] Jirí Cerný,et al. Thermodynamic penalty arising from burial of a ligand polar group within a hydrophobic pocket of a protein receptor. , 2006, Journal of molecular biology.
[9] J. Schellens,et al. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Rubicelia Vargas,et al. How Strong Is the Cα−H···OC Hydrogen Bond? , 2000 .
[11] Yusuke Nakamura,et al. Diaminopyridine-based potent and selective mps1 kinase inhibitors binding to an unusual flipped-Peptide conformation. , 2012, ACS medicinal chemistry letters.
[12] C. Paweletz,et al. Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells , 2010, The Journal of Biological Chemistry.
[13] P. Graczyk. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. , 2007, Journal of medicinal chemistry.
[14] David R. Liu,et al. Highly Specific, Bi-substrate-Competitive Src Inhibitors from DNA-Templated Macrocycles , 2011, Nature chemical biology.
[15] Li Xing,et al. Scaffold mining of kinase hinge binders in crystal structure database , 2013, Journal of Computer-Aided Molecular Design.
[16] F. Uckun,et al. Crystal Structure of Bruton's Tyrosine Kinase Domain Suggests a Novel Pathway for Activation and Provides Insights into the Molecular Basis of X-linked Agammaglobulinemia* , 2001, The Journal of Biological Chemistry.
[17] G. Blumenschein,et al. Motesanib and advanced NSCLC: experiences and expectations , 2011, Expert opinion on investigational drugs.
[18] Yu-Wei Chang,et al. An enriched structural kinase database to enable kinome‐wide structure‐based analyses and drug discovery , 2010, Protein science : a publication of the Protein Society.
[19] John Kuriyan,et al. A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain , 2006, PLoS biology.
[20] L. Tabernero,et al. Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes. , 2010, Biochemistry.
[21] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[22] D. Xie,et al. X‐Ray Crystal Structure of Bone Marrow Kinase in the X Chromosome: A Tec Family Kinase , 2011, Chemical biology & drug design.
[23] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[24] Arvin C Dar,et al. Small molecule recognition of c-Src via the Imatinib-binding conformation. , 2008, Chemistry & biology.
[25] J. Thornton,et al. Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.
[26] Mark R Player,et al. Crystal Structure of the Tyrosine Kinase Domain of Colony-stimulating Factor-1 Receptor (cFMS) in Complex with Two Inhibitors* , 2006, Journal of Biological Chemistry.
[27] J. Kuriyan,et al. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. , 2007, Structure.
[28] Oliver Hantschel,et al. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. , 2006, Molecular cell.
[29] Yusuke Nakamura,et al. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. , 2015, Bioorganic & medicinal chemistry.
[30] Alexander V Efimov,et al. Relationship between intramolecular hydrogen bonding and solvent accessibility of side‐chain donors and acceptors in proteins , 2003, FEBS letters.
[31] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[32] Rajiv Chopra,et al. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6. , 2010, Journal of medicinal chemistry.
[33] Philip D. Jeffrey,et al. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a , 1998, Nature.
[34] Arup K. Ghose,et al. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[35] Kevin E. Riley,et al. Insights into the strength and origin of halogen bonding: the halobenzene-formaldehyde dimer. , 2007, The journal of physical chemistry. A.